(Q34471577)

2 August 2017

title

The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms (English)

1 reference

2 August 2017

L Santarpia

5

0 references

Niccola Funel

object named as

N Funel

2

0 references

Elisa Giovannetti

object named as

E Giovannetti

16

0 references

Alfredo Falcone

object named as

A Falcone

9

0 references

author name string

S Caponi

1

1 reference

2 August 2017

A E Frampton

3

1 reference

2 August 2017

F Mosca

4

1 reference

2 August 2017

A G Van der Velde

6

1 reference

2 August 2017

L R Jiao

7

1 reference

2 August 2017

N De Lio

8

1 reference

2 August 2017

G Kazemier

10

1 reference

2 August 2017

G A Meijer

11

1 reference

2 August 2017

H M Verheul

12

1 reference

2 August 2017

E Vasile

13

1 reference

2 August 2017

G J Peters

14

1 reference

2 August 2017

U Boggi

15

1 reference

2 August 2017

publication date

8 November 2012

1 reference

2 August 2017

1 reference

2 August 2017

volume

24

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

734-741

1 reference

Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Intraductal papillary mucinous neoplasms of the pancreas: an updated experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA expression profiles classify human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Expression profiling identifies microRNA signature in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA miR-155 is a biomarker of early pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNAs modulate the chemosensitivity of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS513

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS513

1 reference

2 August 2017

1 reference